Crystalys Therapeutics raised an oversubscribed $130 million Series B to accelerate dotinurad through Phase 3 registration-directed trials and commercialization preparation. The round is intended to fund late-stage development across RUBY and Topaz Phase 3 trials and the AMETHYST Phase 2 study, supporting a broad clinical program for the once-daily oral URAT1 inhibitor. Dotinurad targets gout patients with unmet needs, and the company framed the funding as backing multiple clinical and regulatory milestones through late-stage data readouts and readiness activities for potential launch. Crystalys said the syndicate included both new and existing investors, with Frazier Life Sciences leading and other healthcare investors participating. For the urate-lowering category, the financing signals continuing capital appetite for differentiating mechanisms and oral convenience—especially as established therapies face penetration and adherence challenges.